258 related articles for article (PubMed ID: 38275869)
1. The Immune Landscape and Immunotherapeutic Strategies in Platinum-Refractory Testicular Germ Cell Tumors.
Evmorfopoulos K; Marsitopoulos K; Karachalios R; Karathanasis A; Dimitropoulos K; Tzortzis V; Zachos I; Vlachostergios PJ
Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38275869
[TBL] [Abstract][Full Text] [Related]
2. Immune checkpoint inhibitors and Chimeric Antigen Receptor (CAR)-T cell therapy: Potential treatment options against Testicular Germ Cell Tumors.
Schepisi G; Gianni C; Cursano MC; Gallà V; Menna C; Casadei C; Bleve S; Lolli C; Martinelli G; Rosti G; De Giorgi U
Front Immunol; 2023; 14():1118610. PubMed ID: 36860862
[TBL] [Abstract][Full Text] [Related]
3. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy in Testicular Germ Cell Tumors.
Kalavska K; Schmidtova S; Chovanec M; Mego M
Front Oncol; 2020; 10():573977. PubMed ID: 33072608
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors.
Cierna Z; Mego M; Miskovska V; Machalekova K; Chovanec M; Svetlovska D; Hainova K; Rejlekova K; Macak D; Spanik S; Ondrus D; Kajo K; Mardiak J; Babal P
Ann Oncol; 2016 Feb; 27(2):300-5. PubMed ID: 26598537
[TBL] [Abstract][Full Text] [Related]
6. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
7. Metabolic interventions combined with CTLA-4 and PD-1/PD-L1 blockade for the treatment of tumors: mechanisms and strategies.
Liao L; Xu H; Zhao Y; Zheng X
Front Med; 2023 Oct; 17(5):805-822. PubMed ID: 37897562
[TBL] [Abstract][Full Text] [Related]
8. Response to anti-programmed cell death protein-1 antibodies in men treated for platinum refractory germ cell cancer relapsed after high-dose chemotherapy and stem cell transplantation.
Zschäbitz S; Lasitschka F; Hadaschik B; Hofheinz RD; Jentsch-Ullrich K; Grüner M; Jäger D; Grüllich C
Eur J Cancer; 2017 May; 76():1-7. PubMed ID: 28262583
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy: last bullet in platinum refractory germ cell testicular cancer.
Semaan A; Haddad FG; Eid R; Kourie HR; Nemr E
Future Oncol; 2019 Feb; 15(5):533-541. PubMed ID: 30624089
[TBL] [Abstract][Full Text] [Related]
10. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
[TBL] [Abstract][Full Text] [Related]
11. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
12. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
13. Current status of clinical trial research and application of immune checkpoint inhibitors for non-small cell lung cancer.
Wang F; Xia T; Li Z; Gao X; Fang X
Front Oncol; 2023; 13():1213297. PubMed ID: 37727216
[TBL] [Abstract][Full Text] [Related]
14. Molecular Mechanisms of Cisplatin Chemoresistance and Its Circumventing in Testicular Germ Cell Tumors.
Schmidtova S; Kalavska K; Kucerova L
Curr Oncol Rep; 2018 Sep; 20(11):88. PubMed ID: 30259297
[TBL] [Abstract][Full Text] [Related]
15. Expression of programmed death ligand-1 (PD-L1) in metastatic and postchemotherapy viable testicular germ cell tumors.
Al-Hogbani M; Duguay J; Wagner DC; Haferkamp A; Joubert P; Frees S; Rendon R; Power N; Périgny M; Toren P
Urol Oncol; 2021 May; 39(5):303.e1-303.e8. PubMed ID: 33685799
[TBL] [Abstract][Full Text] [Related]
16. Immune mechanisms and possible immune therapy in testicular germ cell tumours.
Chovanec M; Mardiak J; Mego M
Andrology; 2019 Jul; 7(4):479-486. PubMed ID: 31169364
[TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials.
Poulose JV; Kainickal CT
World J Clin Oncol; 2022 May; 13(5):388-411. PubMed ID: 35662989
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of avelumab in multiple relapsed/refractory germ cell cancer.
Mego M; Svetlovska D; Chovanec M; Rečkova M; Rejlekova K; Obertova J; Palacka P; Sycova-Mila Z; De Giorgi U; Mardiak J
Invest New Drugs; 2019 Aug; 37(4):748-754. PubMed ID: 31152292
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of relapsed/refractory extracranial germ cell tumors treated on conventional salvage chemotherapy without stem cell rescue: Experience from a tertiary cancer center.
Ramanathan S; Prasad M; Vora T; Badira CP; Kembhavi S; Ramadwar M; Khanna N; Laskar S; Muckaden MA; Qureshi S; Banavali S; Chinnaswamy G
Pediatr Blood Cancer; 2023 Apr; 70(4):e30179. PubMed ID: 36645132
[TBL] [Abstract][Full Text] [Related]
20. Platinum-based chemotherapy in combination with PD-1/PD-L1 inhibitors: preclinical and clinical studies and mechanism of action.
Xue Y; Gao S; Gou J; Yin T; He H; Wang Y; Zhang Y; Tang X; Wu R
Expert Opin Drug Deliv; 2021 Feb; 18(2):187-203. PubMed ID: 32954856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
